{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:25:27Z","timestamp":1789179927141,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY031041"],"award-info":[{"award-number":["R01EY031041"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY026578"],"award-info":[{"award-number":["R01EY026578"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30EY001765"],"award-info":[{"award-number":["P30EY001765"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13346-021-00987-6","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T16:31:08Z","timestamp":1619454668000},"page":"826-837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells"],"prefix":"10.1007","volume":"12","author":[{"given":"Yoo Chun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry T.","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Berlinicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyounkoo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avelina","family":"Hemingway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirby T.","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee Ti","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HyeYoung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Appell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Kolodziejski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Eberhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"Zack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6949-7911","authenticated-orcid":false,"given":"Laura M.","family":"Ensign","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"987_CR1","doi-asserted-by":"publisher","first-page":"1683430","DOI":"10.1155\/2017\/1683430","volume":"2017","author":"TM Atey","year":"2017","unstructured":"Atey TM, et al. The impact of adherence and instillation proficiency of topical glaucoma medications on intraocular pressure. J Ophthalmol. 2017;2017:1683430.","journal-title":"J Ophthalmol"},{"issue":"12","key":"987_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11095-018-2519-x","volume":"35","author":"GA Rodrigues","year":"2018","unstructured":"Rodrigues GA, et al. Topical drug delivery to the posterior segment of the eye: addressing the challenge of preclinical to clinical translation. Pharm Res. 2018;35(12):245.","journal-title":"Pharm Res"},{"issue":"11","key":"987_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41551-020-00606-8","volume":"4","author":"YC Kim","year":"2020","unstructured":"Kim YC, et al. Gelling hypotonic polymer solution for extended topical drug delivery to the eye. Nat Biomed Eng. 2020;4(11):1053\u201362.","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"987_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","volume":"356","author":"R Roskoski Jr","year":"2007","unstructured":"Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007;356(2):323\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"987_CR5","doi-asserted-by":"crossref","unstructured":"Welsbie DS, et al.\u00a0Enhanced functional genomic screening identifies novel mediators of dual leucine zipper kinase-dependent injury signaling in neurons. Neuron, 2017;94(6): p. 1142\u20131154 e6.","DOI":"10.1016\/j.neuron.2017.06.008"},{"issue":"10","key":"987_CR6","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1073\/pnas.1211284110","volume":"110","author":"DS Welsbie","year":"2013","unstructured":"Welsbie DS, et al. Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. Proc Natl Acad Sci U S A. 2013;110(10):4045\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"987_CR7","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1073\/pnas.1211074110","volume":"110","author":"TA Watkins","year":"2013","unstructured":"Watkins TA, et al. DLK initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury. Proc Natl Acad Sci U S A. 2013;110(10):4039\u201344.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"987_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nn.2290","volume":"12","author":"BR Miller","year":"2009","unstructured":"Miller BR, et al. A dual leucine kinase-dependent axon self-destruction program promotes Wallerian degeneration. Nat Neurosci. 2009;12(4):387\u20139.","journal-title":"Nat Neurosci"},{"key":"987_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.exer.2012.03.004","volume":"98","author":"C Durairaj","year":"2012","unstructured":"Durairaj C, Chastain JE, Kompella UB. Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes. Exp Eye Res. 2012;98:23\u20137.","journal-title":"Exp Eye Res"},{"key":"987_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.addr.2017.12.008","volume":"126","author":"AK Rimpela","year":"2018","unstructured":"Rimpela AK, et al. Implications of melanin binding in ocular drug delivery. Adv Drug Deliv Rev. 2018;126:23\u201343.","journal-title":"Adv Drug Deliv Rev"},{"issue":"26","key":"987_CR11","doi-asserted-by":"publisher","first-page":"9903","DOI":"10.1073\/pnas.0600213103","volume":"103","author":"KG Chen","year":"2006","unstructured":"Chen KG, et al. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci U S A. 2006;103(26):9903\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"987_CR12","first-page":"671","volume":"15","author":"M Salazar","year":"1976","unstructured":"Salazar M, Patil PN. An explanation for the long duration of mydriatic effect of atropine in eye. Invest Ophthalmol. 1976;15(8):671\u20133.","journal-title":"Invest Ophthalmol"},{"key":"987_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jconrel.2018.05.034","volume":"283","author":"AK Rimpela","year":"2018","unstructured":"Rimpela AK, et al. Melanin targeting for intracellular drug delivery: quantification of bound and free drug in retinal pigment epithelial cells. J Control Release. 2018;283:261\u20138.","journal-title":"J Control Release"},{"issue":"5","key":"987_CR14","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1681\/ASN.2017010017","volume":"28","author":"M Laster","year":"2017","unstructured":"Laster M, Norris KC. Lesson learned in mortality and kidney transplant outcomes among pediatric dialysis patients. J Am Soc Nephrol. 2017;28(5):1334\u20136.","journal-title":"J Am Soc Nephrol"},{"key":"987_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.exer.2014.09.010","volume":"128","author":"N Wolkow","year":"2014","unstructured":"Wolkow N, et al. Iron upregulates melanogenesis in cultured retinal pigment epithelial cells. Exp Eye Res. 2014;128:92\u2013101.","journal-title":"Exp Eye Res"},{"issue":"1","key":"987_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1167\/iovs.07-0214","volume":"49","author":"NP Cheruvu","year":"2008","unstructured":"Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2008;49(1):333\u201341.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"987_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1124\/dmd.111.042853","volume":"40","author":"B Speed","year":"2012","unstructured":"Speed B, et al. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. Drug Metab Dispos. 2012;40(3):539\u201355.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"987_CR18","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1021\/acs.molpharmaceut.5b00787","volume":"13","author":"AK Rimpela","year":"2016","unstructured":"Rimpela AK, et al. Drug distribution to retinal pigment epithelium: studies on melanin binding, cellular kinetics, and single photon emission computed tomography\/computed tomography imaging. Mol Pharm. 2016;13(9):2977\u201386.","journal-title":"Mol Pharm"},{"issue":"7","key":"987_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1089\/jop.2012.0226","volume":"29","author":"W Du","year":"2013","unstructured":"Du W, et al. The effect of ocular pigmentation on transscleral delivery of triamcinolone acetonide. J Ocul Pharmacol Ther. 2013;29(7):633\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"8","key":"987_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1211\/002235703322277168","volume":"55","author":"C Ono","year":"2003","unstructured":"Ono C, Tanaka M. Binding characteristics of fluoroquinolones to synthetic levodopa melanin. J Pharm Pharmacol. 2003;55(8):1127\u201333.","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"987_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1570-0232(02)00957-1","volume":"787","author":"MJ Koeberle","year":"2003","unstructured":"Koeberle MJ, et al. Development of a liquid chromatography-mass spectrometric method for measuring the binding of memantine to different melanins. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;787(2):313\u201322.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"10","key":"987_CR22","doi-asserted-by":"publisher","first-page":"7148","DOI":"10.1167\/iovs.10-6374","volume":"52","author":"A Ahmado","year":"2011","unstructured":"Ahmado A, et al. Induction of differentiation by pyruvate and DMEM in the human retinal pigment epithelium cell line ARPE-19. Invest Ophthalmol Vis Sci. 2011;52(10):7148\u201359.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"987_CR23","doi-asserted-by":"publisher","first-page":"119935","DOI":"10.1016\/j.biomaterials.2020.119935","volume":"243","author":"SF Hackett","year":"2020","unstructured":"Hackett SF, et al. Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularization. Biomaterials. 2020;243:119935.","journal-title":"Biomaterials"},{"issue":"5","key":"987_CR24","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman VL, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13(5):1367\u201373.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"987_CR25","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s12035-019-01735-1","volume":"57","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. Differential gamma-synuclein expression in acute and chronic retinal ganglion cell death in the retina and optic nerve. Mol Neurobiol. 2020;57(2):698\u2013709.","journal-title":"Mol Neurobiol"},{"issue":"4","key":"987_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.18240\/ijo.2020.04.18","volume":"8","author":"SM Jiang","year":"2015","unstructured":"Jiang SM, et al. Beta-III-tubulin: a reliable marker for retinal ganglion cell labeling in experimental models of glaucoma. Int J Ophthalmol. 2015;8(4):643\u201352.","journal-title":"Int J Ophthalmol"},{"key":"987_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-7407-8_1","volume":"1695","author":"HA Quigley","year":"2018","unstructured":"Quigley HA. Use of animal models and techniques in glaucoma research: introduction. Methods Mol Biol. 2018;1695:1\u201310.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"987_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1006\/rtph.1998.1243","volume":"28","author":"B Leblanc","year":"1998","unstructured":"Leblanc B, et al. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol. 1998;28(2):124\u201332.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"9","key":"987_CR29","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1097\/IAE.0000000000000179","volume":"34","author":"R Singh","year":"2014","unstructured":"Singh R, et al. Clinical evaluation of pazopanib eye drops in healthy subjects and in subjects with neovascular age-related macular degeneration. Retina. 2014;34(9):1787\u201395.","journal-title":"Retina"},{"issue":"10","key":"987_CR30","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1167\/iovs.08-3148","volume":"50","author":"H Nomoto","year":"2009","unstructured":"Nomoto H, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009;50(10):4807\u201313.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"987_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1167\/iovs.12-10473","volume":"54","author":"T Iwase","year":"2013","unstructured":"Iwase T, et al. Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit. Invest Ophthalmol Vis Sci. 2013;54(1):503\u201311.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"987_CR32","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/eye.2016.103","volume":"30","author":"AP Tse","year":"2016","unstructured":"Tse AP, et al. Glaucoma treatment adherence at a United Kingdom general practice. Eye (Lond). 2016;30(8):1118\u201322.","journal-title":"Eye (Lond)"},{"issue":"4","key":"987_CR33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1600-0420.2007.00882.x","volume":"85","author":"A Chawla","year":"2007","unstructured":"Chawla A, McGalliard JN, Batterbury M. Use of eyedrops in glaucoma: how can we help to reduce non-compliance? Acta Ophthalmol Scand. 2007;85(4):464.","journal-title":"Acta Ophthalmol Scand"},{"issue":"2","key":"987_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/ICU.0000000000000334","volume":"28","author":"AA Aref","year":"2017","unstructured":"Aref AA. Sustained drug delivery for glaucoma: current data and future trends. Curr Opin Ophthalmol. 2017;28(2):169\u201374.","journal-title":"Curr Opin Ophthalmol"},{"issue":"6","key":"987_CR35","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jaapos.2009.10.003","volume":"13","author":"AC Black","year":"2009","unstructured":"Black AC, et al. Latanoprost in pediatric glaucoma\u2013pediatric exposure over a decade. J AAPOS. 2009;13(6):558\u201362.","journal-title":"J AAPOS"},{"issue":"7","key":"987_CR36","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1517\/13543784.2011.579901","volume":"20","author":"P Fogagnolo","year":"2011","unstructured":"Fogagnolo P, Rossetti L. Medical treatment of glaucoma: present and future. Expert Opin Investig Drugs. 2011;20(7):947\u201359.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"987_CR37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/1011-1344(92)85027-R","volume":"12","author":"T Sarna","year":"1992","unstructured":"Sarna T. Properties and function of the ocular melanin\u2013a photobiophysical view. J Photochem Photobiol B. 1992;12(3):215\u201358.","journal-title":"J Photochem Photobiol B"},{"issue":"3","key":"987_CR38","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1751-1097.2008.00316.x","volume":"84","author":"DN Hu","year":"2008","unstructured":"Hu DN, Simon JD, Sarna T. Role of ocular melanin in ophthalmic physiology and pathology. Photochem Photobiol. 2008;84(3):639\u201344.","journal-title":"Photochem Photobiol"},{"issue":"5\u20136","key":"987_CR39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0891-5849(98)00234-2","volume":"26","author":"M Rozanowska","year":"1999","unstructured":"Rozanowska M, et al. Free radical scavenging properties of melanin interaction of eu- and pheo-melanin models with reducing and oxidising radicals. Free Radic Biol Med. 1999;26(5\u20136):518\u201325.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"987_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1755-148X.2007.00415.x","volume":"21","author":"K Wakamatsu","year":"2008","unstructured":"Wakamatsu K, et al. Characterization of melanin in human iridal and choroidal melanocytes from eyes with various colored irides. Pigment Cell Melanoma Res. 2008;21(1):97\u2013105.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"12","key":"987_CR41","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1021\/acs.molpharmaceut.9b00769","volume":"16","author":"P Jakubiak","year":"2019","unstructured":"Jakubiak P, et al. Establishment of an in vitro-in vivo correlation for melanin binding and the extension of the ocular half-life of small-molecule drugs. Mol Pharm. 2019;16(12):4890\u2013901.","journal-title":"Mol Pharm"},{"issue":"11","key":"987_CR42","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s11095-007-9342-0","volume":"24","author":"L Pitkanen","year":"2007","unstructured":"Pitkanen L, et al. Binding of betaxolol, metoprolol and oligonucleotides to synthetic and bovine ocular melanin, and prediction of drug binding to melanin in human choroid-retinal pigment epithelium. Pharm Res. 2007;24(11):2063\u201370.","journal-title":"Pharm Res"},{"issue":"3\u20134","key":"987_CR43","first-page":"319","volume":"7","author":"K Steiner","year":"1990","unstructured":"Steiner K, Buhring KU, Merck E. The melanin binding of bisoprolol and its toxicological relevance. Lens Eye Toxic Res. 1990;7(3\u20134):319\u201333.","journal-title":"Lens Eye Toxic Res"},{"issue":"1","key":"987_CR44","first-page":"79","volume":"197","author":"M Salazar","year":"1976","unstructured":"Salazar M, Shimada K, Patil PN. Iris pigmentation and atropine mydriasis. J Pharmacol Exp Ther. 1976;197(1):79\u201388.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"987_CR45","first-page":"708","volume":"23","author":"AA Acheampong","year":"1995","unstructured":"Acheampong AA, Shackleton M, Tang-Liu DD. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos. 1995;23(7):708\u201312.","journal-title":"Drug Metab Dispos"},{"issue":"14","key":"987_CR46","first-page":"2466","volume":"52","author":"JA Burke","year":"2011","unstructured":"Burke JA, et al. The role of ocular pigmentation in the intraocular pressure response to brimonidine in rabbits. Invest Ophthalmol Vis Sci. 2011;52(14):2466\u20132466.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"987_CR47","first-page":"248","volume":"26","author":"M Araie","year":"1982","unstructured":"Araie M, et al. Beta-adrenergic blockers: ocular penetration and binding to the uveal pigment. Jpn J Ophthalmol. 1982;26(3):248\u201363.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"987_CR48","first-page":"32","volume":"37","author":"A Nagata","year":"1993","unstructured":"Nagata A, et al. Binding of antiglaucomatous drugs to synthetic melanin and their hypotensive effects on pigmented and nonpigmented rabbit eyes. Jpn J Ophthalmol. 1993;37(1):32\u20138.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"987_CR49","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41467-020-14340-x","volume":"11","author":"H Tsujinaka","year":"2020","unstructured":"Tsujinaka H, et al. Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles. Nat Commun. 2020;11(1):694.","journal-title":"Nat Commun"},{"issue":"7","key":"987_CR50","first-page":"527","volume":"18","author":"CI Coleman","year":"2012","unstructured":"Coleman CI, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527\u201339.","journal-title":"J Manag Care Pharm"},{"issue":"6","key":"987_CR51","first-page":"e22","volume":"15","author":"SD Saini","year":"2009","unstructured":"Saini SD, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22-33.","journal-title":"Am J Manag Care"},{"issue":"7\u20138","key":"987_CR52","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.repc.2014.01.013","volume":"33","author":"D Caldeira","year":"2014","unstructured":"Caldeira D, Vaz-Carneiro A, Costa J. The impact of dosing frequency on medication adherence in chronic cardiovascular disease: systematic review and meta-analysis. Rev Port Cardiol. 2014;33(7\u20138):431\u20137.","journal-title":"Rev Port Cardiol"},{"issue":"8","key":"987_CR53","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12325-012-0040-x","volume":"29","author":"F Laliberte","year":"2012","unstructured":"Laliberte F, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012;29(8):675\u201390.","journal-title":"Adv Ther"},{"issue":"9","key":"987_CR54","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1185\/030079905X61875","volume":"21","author":"JA Cramer","year":"2005","unstructured":"Cramer JA, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21(9):1453\u201360.","journal-title":"Curr Med Res Opin"},{"key":"987_CR55","doi-asserted-by":"crossref","unstructured":"Iglay K, et al.\u00a0Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy. Clin Ther, 2015. 37(8): p. 1813\u201321 e1.","DOI":"10.1016\/j.clinthera.2015.05.505"},{"issue":"10","key":"987_CR56","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.clinthera.2006.10.013","volume":"28","author":"JA Cramer","year":"2006","unstructured":"Cramer JA, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther. 2006;28(10):1686\u201394.","journal-title":"Clin Ther"},{"key":"987_CR57","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/DMSO.S99732","volume":"9","author":"Q Qiao","year":"2016","unstructured":"Qiao Q, et al. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diabetes Metab Syndr Obes. 2016;9:201\u20135.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"987_CR58","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s13300-019-0643-1","volume":"10","author":"H Ishii","year":"2019","unstructured":"Ishii H, et al. Randomized multicenter evaluation of quality of life and treatment satisfaction in type 2 diabetes patients receiving once-weekly trelagliptin versus a daily dipeptidyl peptidase-4 inhibitor. Diabetes Ther. 2019;10(4):1369\u201380.","journal-title":"Diabetes Ther"},{"key":"987_CR59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.diabres.2019.05.025","volume":"153","author":"H Ito","year":"2019","unstructured":"Ito H, et al. Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes. Diabetes Res Clin Pract. 2019;153:41\u20138.","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"987_CR60","doi-asserted-by":"publisher","first-page":"e787","DOI":"10.1097\/IJG.0000000000000504","volume":"25","author":"M Waisbourd","year":"2016","unstructured":"Waisbourd M, et al. The Wills Eye Glaucoma app: interest of patients and their caregivers in a smartphone-based and tablet-based glaucoma application. J Glaucoma. 2016;25(9):e787\u201391.","journal-title":"J Glaucoma"},{"key":"987_CR61","unstructured":"ADAGIO Study provides evidence that GB-102 can achieve sustained-drug delivery in the treatment of wet age-related macular degeneration (AMD). [cited 2020 Dec. 26th]; Available from: https:\/\/www.graybug.vision\/graybug-vision-presents-top-line-results-of-phase-1-2a-adagio-study-at-hawaiian-eye-retina-2019\/."},{"key":"987_CR62","unstructured":"A depot formulation of sunitinib malate (GB-102) compared to aflibercept in subjects with wet AMD (ALTISSIMO) (ClinicalTrials.gov Identifier: NCT03953079). [cited 2020 Dec. 26th]."}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-00987-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-021-00987-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-00987-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T10:56:26Z","timestamp":1706180186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-021-00987-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["987"],"URL":"https:\/\/doi.org\/10.1007\/s13346-021-00987-6","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"15 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors give consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y.C.K., L.M.E., H.T.H., and J.H. are inventors on patents\/patent applications related to this technology. J.H. and L.M.E. are co-founders of a start-up company planning to develop the eye drop technology for clinical use. DJZ and CAB are inventors on patents related to sunitinib and neuroprotection. Some of these patents have been licensed to Graybug Vision and to Oriole Therapeutics. J.H. is a co-founder and equity owner of Graybug Vision, and both J.H. and Johns Hopkins own company stock. DJZ is a co-founder and equity owner in Oriole Therapeutics. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The contents is solely the responsibility of the authors and does not necessarily represent the official view of the NCATS or NIH.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}